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Abstract
Objectives—Tenofovir (TDF) is increasingly used in second-line antiretroviral treatment (ART)
in sub-Saharan Africa. We compared outcomes of second-line ART containing and not containing
TDF in cohort studies from Zambia and the Republic of South Africa (RSA).
Methods—Patients aged ≥ 16 years starting protease inhibitor-based second-line ART in Zambia
(1 cohort) and RSA (5 cohorts) were included. We compared mortality, immunological failure (all
cohorts) and virological failure (RSA only) between patients receiving and not receiving TDF.
Competing risk models and Cox models adjusted for age, sex, CD4 count, time on first-line ART
and calendar year were used to analyse mortality and treatment failure, respectively. Hazard ratios
(HRs) were combined in fixed-effects meta-analysis.
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Findings—1,687 patients from Zambia and 1,556 patients from RSA, including 1,350 (80.0%)
and 206 (13.2%) patients starting TDF, were followed over 4,471 person-years. Patients on TDF
were more likely to have started second-line ART in recent years, and had slightly higher baseline
CD4 counts than patients not on TDF. Overall 127 patients died, 532 were lost to follow-up and
240 patients developed immunological failure. In RSA 94 patients had virologic failure.
Combined HRs comparing tenofovir with other regimens were 0.60 (95% CI 0.41–0.87) for
immunologic failure and 0.63 (0.38–1.05) for mortality. The HR for virologic failure in RSA was
0.28 (0.09–0.90).
Conclusions—In this observational study patients on TDF-containing second-line ART were
less likely to develop treatment failure than patients on other regimens. TDF seems to be an
effective component of second-line ART in southern Africa.
Keywords
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INTRODUCTION
Despite the unprecedented scale-up of antiretroviral treatment (ART) in resource-
constrained settings, the proportion of patients switching to second-line ART after failing a
first-line regimen is low in many resource-limited countries. Earlier detection of treatment
failure and switching to second-line protease-inhibitor (PI)-based ART probably reduces
mortality 2, but second-line regimens remain considerably more expensive than first line
regimens. Only few studies have described clinical outcomes of patients on second-line
therapy in sub-Saharan Africa 3–6.
As genotypic drug-resistance testing is not routinely available in the region, the World
Health Organization (WHO) recommends the use of standardized second-line ART
consisting of a ritonavir-boosted PI plus two nucleoside reverse transcriptase inhibitors
(NRTIs). The NRTI backbone should include at least one new agent. Tenofovir (TDF) is
increasingly used as a component of second-line ART in patients not previously exposed to
this drug. In southern Africa TDF has only recently been introduced for use in first-line
ART and the majority of patients failing their first-line regimen are therefore eligible to
receive this drug in second-line ART. Although studies from Europe and North America
showed favorable clinical outcomes in patients treated with TDF-containing salvage ART8,9,
outcomes of second-line regimens containing and not containing TDF have not been
compared so far in southern Africa.
HIV-1 subtype C variant represents approximately 50% of global HIV infections and is most
prevalent in southern Africa. The K65R mutation, which is associated with TDF resistance,
is more frequent in HIV-1 subtype C compared to subtype B viruses, especially when
suboptimal first-line regimens including stavudine (D4T) or didanosine (ddI) are used 10–12.
A study from Malawi showed that 23% of patients failing first-line ART developed the
K65R mutation even without prior exposure to TDF 11. In South Africa, where routine viral
load monitoring shortens the time patients spend on failing first-line regimens, the
proportion of patients with this mutation was much lower 13–15. In Malawi clinical outcomes
after one year were not affected by resistance 6.
We compared outcomes in patients receiving TDF-containing second-line ART with those
on other second-line regimens in a collaborative analysis of six cohorts in Zambia and the
Republic South Africa (RSA).
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METHODS
Antiretroviral treatment programmes
The International epidemiological Databases to Evaluate AIDS in Southern Africa (IeDEA-
SA) are a regional collaboration of ART programmes 16. Data are collected at ART
initiation (baseline) and each follow-up visit, using standardized instruments, and transferred
to data centres at the Universities of Cape Town, Republic of South Africa (RSA) and Bern,
Switzerland. All sites have ethical approval to collect data and to participate in IeDEA-SA.
We included all cohorts with more than 50 patients on second-line ART, and 10 or more
patients on TDF and not on TDF. Six cohorts met inclusion criteria: the Centre for
Infectious Disease Research in Zambia (MoH-CIDRZ) programme in Lusaka, Zambia and
five cohorts from RSA: Aurum Institute (community and workplace ART program) and
Themba Lethu clinic in Johannesburg, and the Khayelitsha and Tygerberg ART programs in
Cape Town. In RSA viral load and CD4 cell counts are monitored every 6 months during the
first year of ART and then yearly. In Zambia CD4 counts are monitored every 6 months but
viral load measurements are not routinely performed. All treatment programmes trace
patients lost to follow-up.
Eligibility criteria
All patients aged 16 years and older who started a second-line ART regimen were included.
We defined second-line regimens according to the most recent WHO treatment guidelines as
a boosted PI-based regimen, which followed a first-line regimen of one NNRTI and two
NRTIs. At least one component of the NRTI backbone had to be replaced by a drug
characterised by different resistance mutations pathways. For example, a change from
lamivudine (3TC)/D4T to 3TC/zidovudine (AZT) was not considered an eligible backbone
change. Patients with ineligible backbone changes and patients treated with a TDF-
containing first-line regimen were excluded. The selection of study participants in Zambia
and the Republic of South Africa are shown in Webfigures 1 and 2.
Outcomes
We examined time to immunological failure, time to virological failure and time to death,
defining treatment failure as proposed by WHO. Briefly, there are 3 possible criteria for
immunological failure: (i) a fall of CD4 count to baseline or below, (ii) a 50% fall from on-
treatment peak value and (iii) persistent CD4 count levels below 100 cells/μl. Patients were
considered to experience immunological failure if at least one of the 3 criteria were fulfilled
on two consecutive CD4 cell measurements within 1 year. Virological failure, defined as 2
consecutive viral load measurements above 5,000 copies/ml within a year, was assessed in
the South African cohorts.
Statistical analyses
Characteristics at the start of second-line ART were compared between patients on second-
line regimens containing and not containing TDF using chi-squared and Mann-Whitney
tests. We compared rates of immunological failure and virological failure in Cox regression
models, measuring time from 6 months after switching to second-line ART. We used
competing risk cumulative incidence curves 17 and competing risk regression models
according to Fine and Gray 18 to compare mortality, measuring time from switching to
second-line ART. Standard Kaplan-Meier curves ignore the competing risks of death and
LTFU and may produce biased results19. All regression models included the variables
gender, age (16–29, 30–39 or 40 years and over), CD4 cell count (0–49, 50–99, 100–199,
over 200 cells/μl or “not measured”) at the start of second-line ART, time on first-line
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before switching to second-line ART (less than 18, 18–36 or over 36 months) and calendar
year of starting second-line ART (before 2007, 2007, 2008, 2009 and 2010).
All analyses were done separately for Zambia and RSA. Sub-distribution hazard ratios
(sHR) and hazard ratios (HR) were then combined in (inverse variance weighted) fixed-
effects meta-analysis and shown in a stratified forest plot. Finally, in order to assess the
effect of the first-line backbone on second-line outcomes, we examined whether the use of
D4T in the first-line ART regimen predicted immunological failure in patients on TDF-
containing second-line regimen. All statistical analyses were performed using Stata software
version 11 (College Station, Texas, USA).
RESULTS
ART programmes and patients characteristics
Table 1 shows the composition of cohorts. A total of 3,243 patients on second-line ART,
including 1,556 (48.0%) on a TDF-containing regimen were included in the analyses. The
majority of patients were female in all cohorts except the workplace cohort in South Africa,
which was dominated by male miners. The median age ranged from 32 years in Khayelitsha
to 45 years in the Aurum workplace cohort. In Zambia, 80% of patients were on TDF-based
second-line ART whereas in RSA this percentage ranged from 4% to 25%. Crude mortality
rates were similar across South African cohorts except for the Aurum community cohort for
which mortality was considerably lower, probably due to under ascertainment of deaths.
Such under ascertainment may also explain the lower mortality in Zambia compared to
RSA.
Both in Zambia and RSA, the proportion of patients on a TDF containing second-line
regimen increased over the years, with the exception of a slight decrease in Zambia in 2010
(Table 2). The median age at start of second-line ART was higher in patients on TDF in
Zambia, but identical in both treatment groups in RSA. Conversely, the sex distribution was
similar in Zambia whereas in RSA, women were more likely to start a TDF containing
regimen than men. In both countries, patients receiving TDF-containing regimens had higher
CD4 cell counts and had spent more time on their first-line regimen before switching to
second-line ART than those on other regimens. Most patients (3,225 patients; 99.4%) were
treated with second-line regimens containing ritonavir-boosted lopinavir (LPV/r) and 1,468
(87.0%) of the patients not on a TDF-containing second-line regimen had a backbone of
DDI/AZT or DDI/ABC.
Descriptive analyses of treatment failure, mortality and LTFU
Analyses of immunological treatment failure were based on 2,330 patients (71.8% of total
study population) with at least six months of follow-up after starting second-line ART.
Virological failure was examined in 992 patients (63.8% of patients treated in RSA). Over
2,782 person-years, 94 patients (7.9%) on TDF and 146 patients (12.8%) on other second-
line regimens developed immunological failure. The crude incidence rate of immunological
failure was 69.9 (95% CI 57.1–85.6) per 1,000 person-years in the TDF group and 101.6
(86.4–119.4) per 1,000 person-years in the other group. In South Africa, three patients
(2.7%) in the TDF group and 107 patients (12.1%) in the group without TDF experienced
virological failure. Figure 1 shows the Kaplan-Meier curves of immunological failure in
Zambia and virological failure in South Africa, by treatment group.
Over 4,471 person-years, 127 patients (3.9%) died and 532 (16.4%) were LTFU (Table 1).
Crude rates per 1000 person-years ranged from 6.5 (95% CI 1.6–25.9) to 45.2 (27.3–75.0)
for mortality and from 54.6 (34.4–86.7) to 165.8 (127.3–216.0) for LTFU. Figure 2 shows
the cumulative incidence of mortality and LTFU by country and type of second-line ART
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from the competing risk analysis. At 3 years, 3.3% of patients (95% CI 2.3–4.5%) in the
TDF group in Zambia and 4.4% (95% CI 1.8–8.8) in South Africa were known to have died.
These proportions were higher in the groups treated without TDF: 9.0% (95% CI 6.9–
12.7%) in Zambia and 7.8% (95% CI 5.8–10.00) in South Africa. LTFU at 3 years was
higher in Zambia than in RSA. In Zambia, LTFU was somewhat higher in patients on TDF
compared to patients not on TDF whereas the opposite was observed in RSA: LTFU was
lower in patients on TDF compared to other patients (Figure 2). These analyses were not
adjusted for differences in patient characteristics at the start of second-line ART and
therefore have to be interpreted with caution.
Regression analyses of treatment failure and mortality
Figure 3 presents the results from the Cox and competing risk regression analyses adjusted
for age, sex, CD4 count, time on first-line ART and calendar year, and meta-analyses of
these estimates. Results for immunological failure were closely similar in Zambia and RSA
(p from test of heterogeneity 0.99), with a combined HR comparing TDF with other
regimens of 0.60 (95% CI 0.41–0.87). Similarly, the hazard of virologic failure was reduced
with TDF in RSA: HR 0.22 (95% CI 0.07–0.71). Mortality was lower in patients on a TDF-
containing regimen compared to those on other regimens in Zambia but not in RSA.
However, confidence intervals overlapped and the test of heterogeneity was not statistically
significant (p=0.13). The combined subdistribution HR for mortality was 0.63 (95% CI
0.38–1.05).
Results for all variables included in the models are shown in webtable 1 for Zambia and
webtable 2 for RSA. In both settings, male patients and those under 30 years of age were
more likely to experience treatment failure. Time spent on first-line ART before switching
to a second-line regimen did not affect outcomes. Finally, in patients on TDF-containing
second-line regimens, the risk of second-line immunological failure in the TDF-group was
slightly increased if D4T was used in the first-line backbone, however, confidence intervals
around the HR (adjusted for all variables listed above) were wide and included both a
decrease and increase of the risk of failure: HR 1.30 (95% CI 0.84–2.02).
DISCUSSION
Even though several countries in southern Africa have introduced TDF in first-line ART,
most patients who will be failing their first-line regimen in the coming years will not have
been exposed to TDF. As a consequence, these patients might benefit from this drug in their
second-line regimen. The comparative effectiveness of second-line regimens including or
excluding TDF in southern Africa is therefore of great interest. We compared clinical
outcomes between patients receiving TDF-containing second-line ART and patients treated
with other second-line regimens in six ART programmes in Zambia and RSA. Overall,
mortality and the rate of treatment failure were low in this population, underlining the
benefit of PI-based second-line ART in patients failing first-line treatment in the region20. In
Zambia, LTFU was similar in patients on second-line ART containing and not containing
TDF, but mortality and immunological failure were lower in patients on TDF. In the five
South African cohorts with access to routine viral load monitoring the rate of virological
failure was also lower in the TDF group.
In contrast to Zambia the use of TDF was not associated with reduced mortality in South
Africa. This finding could be the result of differences in the capacity of the health system in
South Africa compared to Zambia or reflect differences in ascertainment of deaths and
tracing of patients LTFU. Confounding by indication could be another explanation: the
relatively few patients who were prescribed TDF in South Africa before 2010 might have
been a selected group of sicker patients. Finally, the difference between the two countries
Wandeler et al. Page 5
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2013 September 01.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
could reflect the play of chance: the confidence intervals overlapped widely and a formal
test of heterogeneity gave a p value of 0.13. We can thus not exclude a similar reduction in
mortality in RSA.
In both groups mortality after one year of second-line ART was somewhat lower than the
5.4% mortality observed after a median of 15.1 months in the Médecins sans Frontiéres
(MSF) multi-cohort study of patients on second-line ART 3. In contrast, in a study of
patients virologically failing first-line ART in Malawi, 10% of patients on second-line ART
died during the first six months 6. The higher mortality in the latter study might be explained
by the presence of virological failure in all patients and the very low median CD4 count at
the start of second-line ART. Furthermore, patients who are treated in settings without
access to routine viral load monitoring are at risk of remaining on failing first-line regimens
for long periods before switching to second-line ART2,21, and of accumulating drug
resistance mutations which might limit the efficacy of some second line regimens11.
Studies from different regions in sub-Saharan Africa showed a high prevalence of TDF-
related resistance mutations in patients failing first-line ART 10,11,22. This raised concerns
on the efficacy of TDF in second-line regimens for populations infected with subtype C
HIV-1 variants. In high-income countries, the K65R mutation is present only in 2–5% of
HIV-1 subtype B infected patients failing first-line ART 23. In contrast, over 20% of patients
failing first-line ART in an urban public-sector ART clinic in Malawi had developed this
resistance mutation, without prior exposure to TDF 11. Interestingly, in the Malawian study,
and the PharmAccess African Studies to Evaluate Resistance (PASER), clinical outcomes
one year after initiation of second-line ART were not affected by resistance to TDF 6,24.
Another report from PASER nevertheless argued that in light of the high prevalence of the
K65R mutation in patients failing a D4T-containing regimen, AZT might be a better option
for second-line ART than TDF12. Prolonged treatment with a failing D4T-containing first-
line regimen might explain the high levels of TDF resistance mutations in the region 23. We
found little evidence for an association of the risk of second-line treatment failure with the
presence of D4T in the first-line regimen, however, the power of our study to detect smaller
effects was limited.
There are several possible explanations for the superior effect of TDF in second-line ART in
Zambia and South Africa. More than 80% of the patients not on TDF were treated with
either DDI/AZT or DDI/ABC as the NRTI backbone. Due to its better tolerability and once-
daily dosing, treatment adherence might be higher in patients receiving TDF compared to
other NRTI combinations, especially those including DDI: the higher toxicity of DDI-based
regimens might have led to poorer adherence. Wallis et al. and Van Zyl et al. reported a low
prevalence of PI mutations in patients failing second-line ART in the Republic of South
Africa 25,26, indicating that failure was due to insufficient drug levels following non-
adherence, rather than resistance. Finally, the high potency of LPV/r monotherapy in
patients without prior PI exposure could have masked larger differences in treatment
outcomes between the two groups 27,28. Patients on TDF-containing second-line regimens
might have had favourable outcomes despite potential NRTI mutations, including
thymidine-analogue mutations (TAM’s) and K65R. Of note, the difference in treatment
failure between the two second-line regimens emerged already after one year in RSA,
whereas it was only apparent later during follow-up in Zambia. This could be explained by
the earlier diagnosis of treatment failure with virological monitoring in RSA compared to
CD4 monitoring in Zambia.
To our knowledge this is the first study to compare second-line regimens in southern Africa.
In particular, there are no randomized trials of second-line ART tailored to regions where
non-B HIV subtypes dominate. The main limitation of multi-cohort data comparing
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treatments lies in the lack of randomization and the heterogeneity between the different
treatment sites. Confounding by indication and differences between settings in background
mortality, monitoring and treatment strategies, and health systems may have biased our
results. Of note, the proportion of patients on a TDF-containing second-line regimen varied
widely across countries and calendar time, reflecting national treatment guidelines.
However, the association of TDF with reduced rates of treatment failure was consistent
within countries and cohorts, which adds strength to our findings. Furthermore, over 99% of
the patients received the same PI, thus effectively removing one potential source of
confounding. We had no data on treatment adherence, which is known to influence ART
outcomes29–31. Young age and male gender were risk factors for second-line failure,
probably as a consequence of the lower adherence to ART in younger patients and
men 32,33. Finally, as no genotypic resistance data is routinely collected in southern Africa,
we could not assess the relationship between treatment failure, resistance patterns and
clinical outcomes.
We did not evaluate toxicity and side-effects related to the different regimen. Most patients
on non-TDF second-line ART had DDI in their backbone. The toxicities of DDI, including
lipodystrophy, gastrointestinal intolerance, peripheral neuropathy and pancreatitis, will have
influenced our results.34,35 TDF is associated with nephrotoxicity, including an increased
risk of loss of kidney function, acute renal failure and tubulopathy36,37. A recent study from
South Africa showed that pre-existing renal disease was frequently exacerbated by the use of
tenofovir38. Furthermore, patients on PI-based regimens may be at increased risk of renal
failure39. Screening for renal dysfunction before the initiation of TDF-containing regimen
and close monitoring during treatment is part of treatment guidelines and should be
performed routinely.
In conclusion, we found that patients on TDF-containing second-line ART were less likely
to develop treatment failure in all cohorts and less likely to die in Zambia than patients on
other regimens. Despite the increased prevalence of TDF-related resistance mutations in
patients failing first-line ART in southern Africa, TDF seems to be an effective component
of second-line ART for many patients who have not been exposed to this drug previously.
This finding is of considerable importance, as an increasing number of TDF-unexposed
patients failing their first-line treatment will be switched to TDF-containing second-line
regimen in the coming years. Second-line ART is becoming more available in sub-Saharan
Africa, but most ART programmes in the region do not have access to individual genotypic
resistance data. Thus, randomized trials comparing the efficacy and toxicities of different
second-line regimens are urgently needed to inform clinical practice and guidelines.
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FIGURE 1.
Cumulative incidence of immunological failure in Zambia (A) and virological failure in the
Republic of South Africa (B) during the first three years of second-line ART. TDF,
tenofovir.
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FIGURE 2.
Retention in care by second-line ART category and country.
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FIGURE 3.
The risk of treatment failure and death on secondline ART containing and not containing
tenofovir in Zambia and the Republic of South Africa. The estimates shown are hazard
ratios (HR) for immunological and virological failure and subdistribution hazard ratios
(sHR) for mortality.
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